ZIOPHARM Oncology Inc has received $-0.11 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 4 Financial Advisor in the Stock Trading Firms. Among 4 Analysts, Bottom line EPS Estimate for the current quarter is $-0.12 while the top line estimate is $-0.08 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -53.57%.
In the last quarter, ZIOPHARM Oncology Inc reported Annual Earnings of $-0.11. Based on the filings, last years Annual Earnings was, $-0.42. In the last Quarter, ZIOP reported a surprise Earnings per Share of 0% . The consensus estimate for current quarter is $-0.11 and for the current fiscal year, the estimate is $-0.4. For the Next fiscal year, the estimate is $-0.46 based on the consensus.
ZIOPHARM Oncology Inc (NASDAQ:ZIOP) : On Tuesday heightened volatility was witnessed in ZIOPHARM Oncology Inc (NASDAQ:ZIOP) which led to swings in the share price. The stock opened for trading at $5.75 and hit $6.19 on the upside , eventually ending the session at $5.92, with a gain of 2.07% or 0.12 points. The heightened volatility saw the trading volume jump to 2,251,871 shares. The 52-week high of the share price is $9.74 and the company has a market cap of $780 million. The 52-week low of the share price is at $4.45 .
ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment.